Donate
info@cureduchenne.org(949) 872-2552
EventsContact
Cart
×

No products in the cart.

CureDuchenne
Moble Nav Icon
  • Cure
    • CureDuchenne Link
    • Research Overview
    • Research Terms
    • Exon Skipping
    • Clinical Trials
  • Care
    • COVID-19 Resources
    • Newly Diagnosed
    • Clinic
    • Steroid Use
    • Emergency Care
    • Resource Library
    • DME Guide
    • Medical ID Bracelets
    • Navigating School
    • Occupational Therapy
    • Physical Therapy
    • For Families
    • - Find a Physical Therapist
    • - Pool Activities
    • - Stretching
    • For Physical Therapists
    • - PT Certification
    • - Professional Courses
    • For Clinics
  • Community
    • CureDuchenne CARES
    • CureDuchenne FUTURES
    • CureDuchenne Champions
    • Family Stories
    • Events
    • Previous Webinars
    • Family Fundraisers
  • About Us
    • Mission
    • Vision
    • About Duchenne
    • Blog
    • Board of Directors
    • Sponsors
    • Reports and Financials
    • Events & Webinars
    • News Center
    • - Press Releases
    • - Partner News
    • - Research
  • CD Ventures
    • About CD Ventures
    • Our Impact
  • Get Involved
    • Donate
    • More Ways to Give
    • Fundraise
    • Shop
    • Fundraising Events
    • - Ladies Luncheon Austin
    • - CureDuchenne Golf Shootout | Orange County, CA
    • - Napa in Newport | Orange County, CA
  • Donate
  • All
  • Cure Duchenne Blog
  • Press Releases
  • CureDuchenne In The News
  • Research
Entos Gene Therapy

CureDuchenne’s latest investment aims to address the limitations of current AAV-delivered gene therapy treatments for Duchenne muscular dystrophy (DMD).

June 18, 2025

Our recent investment in Entos Pharmaceuticals (https://entospharma.com) aims to explore the potential of their non-viral, redosable Fusogenix PLV platform to deliver full-length dystrophin protein to all muscle groups in a […]

Read More
Duchenne gene therapy Entos

CureDuchenne Ventures Invests in Entos Pharmaceuticals for Development of a Redosable, Full-Length Dystrophin Gene Therapy

May 22, 2025

Newport Beach, Calif. and Edmonton, Canada (May 22, 2025) – CureDuchenne Ventures announced an initial $1M investment in Entos Pharmaceuticals Inc (Entos), a biotech company that develops genetic medicines utilizing […]

Read More

  • About

    • Mission
    • About Duchenne MD
    • Blog
    • Store
    • News Center

  • Get Involved

    • Donate
    • Fundraising
    • Attend an Event

  • CureDuchenne

    • 100 Bayview Circle, Suite 5600
      Newport Beach, CA 92660
      (949) 872-2552
      info@cureduchenne.org

  • Get Connected

PRIVACY POLICY | TERMS OF USE | INDIRECT COST POLICY | TAX INFO

CureDuchenne is a 501c3 registered tax-exempt nonprofit organization. Federal Tax ID: #20-0299958 | ©2025 CureDuchenne. All rights reserved.

Please be advised that the contents within the CureDuchenne site include a compilation of articles, advisements, and references from the community. CureDuchenne does not provide medical advice nor is CureDuchenne a medical provider. The intent of this shared content is to serve as a point of reference for informational purposes. Please refer to your health care provider(s) for your individualized, specific care management needs. The CureDuchenne website may contain links to external websites that are not provided and/or maintained by or in any way affiliated with CureDuchenne. CureDuchenne recommends that you review the terms of service and privacy policies of these external websites before entering. Please note that CureDuchenne does not guarantee the accuracy, relevance, timeliness, or completeness of any information on these external websites.

We use cookies to ensure that we give you the best experience on our website. By continuing to use this site you are agreeing to accept our use of cookies. For more information about cookies please visit our Privacy Policy page.I Agree